These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6213322)

  • 1. Salivary testosterone: relationship to unbound plasma testosterone in normal and hyperandrogenic women.
    Baxendale PM; Jacobs HS; James VH
    Clin Endocrinol (Oxf); 1982 Jun; 16(6):595-603. PubMed ID: 6213322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and salivary androstenedione and dihydrotestosterone in women with hyperandrogenism.
    Baxendale PM; Jacobs HS; James VH
    Clin Endocrinol (Oxf); 1983 May; 18(5):447-57. PubMed ID: 6223726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
    Frölich M; Lachinsky N; Moolenaar AJ
    Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen levels during cyproterone acetate and ethinyl oestradiol treatment of hirsutism.
    Rubens R
    Clin Endocrinol (Oxf); 1984 Mar; 20(3):313-25. PubMed ID: 6233049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
    Porcile A; Gallardo E
    Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of cyproterone acetate on pituitary-ovarian function and clinical symptoms in hirsute women.
    Lunell NO; Zador G; Carlström K; Eneroth P; Patek E; Wager J
    Acta Endocrinol (Copenh); 1982 May; 100(1):91-7. PubMed ID: 6214134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hair growth and androgen responses in hirsute women treated with continuous cyproterone acetate and cyclical ethinyl oestradiol.
    Jones DB; Ibraham I; Edwards CR
    Acta Endocrinol (Copenh); 1987 Dec; 116(4):497-501. PubMed ID: 2962412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salivary testosterone as an index of antiandrogen therapy in hirsutism.
    Gómez JM; Navarro MA; Arranz B; Soler J; Bonnin MR; Montaña E
    Recenti Prog Med; 1992 Dec; 83(12):672-4. PubMed ID: 1494704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of essential hirsutism in women with cyproterone acetate and ethinyl estradiol. Clinical and endocrine effects in 10 cases.
    Frey H; Aakvaag A
    Acta Obstet Gynecol Scand; 1981; 60(3):295-300. PubMed ID: 6455899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of long-term treatment with cyproterone acetate or a cyproterone acetate-ethinyl oestradiol combination on androgen levels in blood of hirsute women.
    Frölich M; Vader HL; Walma ST; De Rooy HA
    J Steroid Biochem; 1980 Jan; 12():499-501. PubMed ID: 6448324
    [No Abstract]   [Full Text] [Related]  

  • 11. Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination.
    Kokaly W; McKenna TJ
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):379-82. PubMed ID: 10718837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment.
    Luboshitzky R; Herer P; Shen-Orr Z
    Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):102-7. PubMed ID: 15031776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for a non-androgenic anovulant in the management of hirsutism.
    McKenna TJ; Cunningham SK
    Ir J Med Sci; 1991 Jul; 160(7):194-6. PubMed ID: 1757211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severe hirsutism resulting from hyperandrogenism with the reverse sequential cyproterone acetate regimen.
    Garner PR; Poznanski N
    J Reprod Med; 1984 Apr; 29(4):232-6. PubMed ID: 6232380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
    Bhattacharya SM; Jha A
    Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome.
    Karabulut A; Demirlenk S; Sevket O
    Gynecol Endocrinol; 2012 Apr; 28(4):245-8. PubMed ID: 21961995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyproterone acetate as initial treatment and maintenance therapy for hirsutism.
    Holdaway IM; Croxson MS; Ibbertson HK; Sheehan A; Knox B; France J
    Acta Endocrinol (Copenh); 1985 Aug; 109(4):522-9. PubMed ID: 2930987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cyproterone acetate. 15 cases of hirsutism treated for 1 year].
    Houdent C; Kuhn JM; Balacheff O; Leclerc P; Legrand A; Wolf LM
    Ann Endocrinol (Paris); 1983; 44(6):397-401. PubMed ID: 6234850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.